Key facts
- It has raised $52.0M; the latest was Debt - General ($21.0M) in Dec 2024.
- Notable investors include Nordic Secondary Fund, Eurostars, Horizon 2020, ICP Group (Denmark), Technical University of Denmark — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Norlase
- ·The full record, as it builds
Funding rounds
No funding rounds for Norlase are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Norlase
Developer of laser technologies designed for the treatment of retina and glaucoma disease. The company's technologies use a special type of diode to produce powerful lasers and employ photonics technology to design and create their equipment to diagnose sugar in patients, enabling clients to get access to laser technologies for their treatment at an affordable price.
- Sector
- Healthcare
- HQ
- Ballerup, Denmark
- Founded
- 2014
- Employees
- 60
- Website
- norlase.com/
- Ownership
- Privately Held (backing)
Norlase doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Norlase shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Norlase in its N-PORT filings yet. We sweep new filings monthly.